Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

fasinumab

- PMLiVE

US charges Teva for generic drug price-fixing plot

Company maintains it has not committed any wrongdoing

- PMLiVE

Roche, Regeneron partner on COVID-19 antibody cocktail

Collaboration agreement will bolster global development and manufacturing capabilities

- PMLiVE

Regeneron’s COVID-19 antibody cocktail enters phase 3 trial

Drug will be evaluated in preventative trial testing uninfected participants

Sanofi reception

Sanofi doses first patient in global Kevzara COVID-19 trial

Sanofi is leading trials outside the US while Regeneron is leading US trials

- PMLiVE

Sanofi, Regeneron launch trials of arthritis drug Kevzara for COVID-19

The interleukin-6 inhibitor will be evaluated in critically ill patients

- PMLiVE

Teva’s weak pipeline hit by Tourette’s drug trial failure

Drug wasn't able to improve on placebo

- PMLiVE

Regeneron reveals first data for bispecific antibody in multiple myeloma

Could be a pivotal treatment for patients who have exhausted options

- PMLiVE

Trial backs Inovio/Sanofi combo in hard-to-treat brain cancer

Results at six months demonstrated 75% of patients were progression-free

- PMLiVE

Sanofi/Regeneron wins another EU approval for Dupixent

Becomes first biologic approved in EU for CRSwNP indication

- PMLiVE

Regeneron scores positive data in phase 3 cholesterol trial

Targets severe inherited disorder

- PMLiVE

Dupixent drives Sanofi again, but other new drugs are lagging

Reported loss due to restructuring

- PMLiVE

Sanofi/Regeneron’s IO latecomer Libtayo approved in Europe

Licensed to treat one of the most commonly diagnosed skin cancers

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links